Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation (JAKINCOV) (JAKINKOV)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04366232
Recruitment Status : Not yet recruiting
First Posted : April 28, 2020
Last Update Posted : May 22, 2020
Sponsor:
Collaborators:
Hopital d'instruction des Armees Sainte-Anne
Assistance Publique Hopitaux De Marseille
Information provided by (Responsible Party):
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer

Brief Summary:
During SARS-Cov2 infection with serious respiratory implication and high systemic inflammation level, intravenous ANAKINRA alone or associated with RUXOLITINIB for severe cases might reduce inappropriate systemic inflammatory response, improve breathing and decrease occurrence or duration of ARDS and associated mortality.

Condition or disease Intervention/treatment Phase
Covid-19 Drug: Anakinra alone (stages 2b/3) Drug: Anakinra and Ruxolitinib (overcome stage 3) Other: Standard of care Phase 2

Detailed Description:

Two physiopathological phases exist during COVID-19 disease: The early phase is mainly induced by the virus itself. It is imperative not to decrease the immune host response during this phase by prohibiting the use of non steroidal anti-inflammatory drugs or corticosteroids at this stage and developing an anti-viral strategy. The late phase, around Day 7-9, depends only upon host response and is linked to an excessive inflammatory response with a major increase of inflammatory cytokines such as IL-6, MCP-1, GCSF indicative of IL-1b excess, as well as IP-10, MIP-1, indicative of IFNg signature, corresponding to a "cytokine storm". Clinical and biological features during Still's disease (complicated in 10% of cases with hemophagocytosic lymphohistiocytosis inducing cytopenia, hepatic insufficiency, major hyperferritinemia and multi-organ failure) are close to those reported during COVID-19 and underline physiopathological similarities.

Anakinra (KINERET) is an IL-1 pathway (IL-1ra) specific inhibitor that has been used for 15 years, also largely blocking IL-18 production. Adult Still's disease is very effectively treated with anakinra. During sepsis with hyperferritinemia, IL-1ra demonstrated patient survival improvement. Ruxolitinib (JAKAVI) inhibits the downstream IFNg pathway targeting JAK kinase receptor. It has recently proved its efficiency in hemophagocytosic lymphohistiocytosis refractory forms associated with a multi-organ failure.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Assignment to one of two or more groups in parallel during the study No crossover
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Interleukin-1 (IL-1) and Interferon Gamma (IFNg) Inhibition During COVID 19 Inflammation: Randomized, Controlled Study Assessing Efficacy and Safety of Anakinra and Ruxolitinib
Estimated Study Start Date : May 15, 2020
Estimated Primary Completion Date : August 31, 2020
Estimated Study Completion Date : August 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Anakinra +/- Ruxolitinib

According to clinical stage (gradual strategy):

  • Stage 2b or 3 : Anakinra 300 mg IV
  • Overcome stage 3 : Anakinra 300 mg IV and Ruxolitinib 5 mg x 2
Drug: Anakinra alone (stages 2b/3)
Anakinra 300 mg 1/d Intravenous 5 days then dose tapering
Other Name: KINERET

Drug: Anakinra and Ruxolitinib (overcome stage 3)
Anakinra 300 mg od Intravenous (maximum14 days) Ruxolitinib 5 mg bid per os (maximum 28 days)
Other Name: KINERET and JAKAVI

Active Comparator: Standard of care
Treatment with drugs or procedures in routine clinical practice
Other: Standard of care
Routine clinical care for Covid-19




Primary Outcome Measures :
  1. Biological criteria [ Time Frame: 7 days from enrolment ]

    At least 3 parameters are met including CRP and/or Ferritin among:

    1. CRP: decrease > 50%
    2. Ferritinemia: decrease > 1/3
    3. Serum creatinine: decrease > 1/3
    4. AST/ALT: decrease > 50%
    5. Eosinophils > 50 /mm3
    6. Lymphocytes > 1000 /mm3


Secondary Outcome Measures :
  1. Duration of oxygen therapy (days) [ Time Frame: 28 days from enrolment ]
    Number of days without mechanical ventilation

  2. Number of intensive care units admissions [ Time Frame: 28 days from enrolment ]
    Number of patients included in stage 2b

  3. Number of days in intensive care units [ Time Frame: 28 days from enrolment ]
    Number of days in intensive care units for patients managed in intensive care units

  4. Mortality rate [ Time Frame: 28 days from enrolment ]
    Mortality rate

  5. Total number of days in hospital [ Time Frame: 28 days from enrolment ]
    Total number of days in hospital

  6. Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score) [ Time Frame: 28 days from enrolment ]
    Organ failure score modification (Sepsis-related Organ Failure Assessment (SOFA) score); Sofa score's minimum and maximum values are 0 and 24, the lowest score corresponds to a better outcome.

  7. Number of bacterial and/or fungal sepsis [ Time Frame: 28 days from enrolment ]
    Number of bacterial and/or fungal sepsis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmed respiratory tract SARS-coV-2 infection by at least one PCR on nasopharygeal sample or a bronchoalveolar lavage
  • Patient hospitalized with clinical, biological and radiological features corresponding to the following stages :

    • Stage 2b: hypoxic pneumonia (respiratory frequency > 30/mn, Sa02 < 90 mmHg on room air) associated with a clear biological inflammatory syndrome (CRP > 150 mg/l)
    • Stage 3: ARDS defined by a patient under mechanical ventilation with a ratio PaO2/FiO2 < 300 for more than 24h
    • Evolved stage 3: ARDS according to previous definition associated with another organ failure or syndrome among:
  • A state of shock with noradrenaline dosing > 3mg/h
  • Acute kidney failure oligo-anuric or justifying extra-renal purification
  • Hepatocellular insufficiency or coagulopathy with a V factor < 50%
  • Myocarditis responsible for acute heart failure and or cardiogenic shock
  • Hemophagocytic syndrome
  • Hyperferritinemia > 5000 ng/mL
  • Subject or legal representative having expressed written consent after information
  • Subject affiliated to or entitled to a social security regimen
  • Patient presenting in a life-threatening emergency situation that does not allow consent to be obtained

Exclusion Criteria:

  • Pregnancy or lactation
  • Absolute neutrophil count less than 1.5 x 109/L
  • Hepatic transaminases AST or ALT greater than 5 times normal values
  • Platelet count less than 50,000 per mm3
  • Solid organ or hematopoietic stem cell transplant patients
  • Patients treated with immunosuppressants or immunomodulators
  • Use of oral corticosteroids chronically at doses greater than 10 mg prednisone equivalent per day for a non-COVID-19 related condition.
  • Uncontrolled autoimmune disease
  • Patients with active, suspected or known, uncontrolled systemic bacterial, viral (excluding COVID-19) or fungal infections
  • Hypersensitivity to anakinra and/or ruxolitinib and their excipients
  • Vaccinations with live attenuated vaccines in the month prior to inclusion
  • Patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure)
  • Persons deprived of liberty by judicial or administrative decision or major persons under a legal protection measure.
  • Person in exclusion period of another research protocol for SARS-CoV-2 infection.
  • Person not mastering enough French understanding and reading to be able to consent to participate in the study.
  • Persons under psychiatric care pursuant to Articles A3112-1 and L3113-1 who are not covered by the provisions of Article L1121-8
  • Every condition which, according to investigator, might increase and compromise the person security in case of study participation or might interfere with research results.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04366232


Contacts
Layout table for location contacts
Contact: Jean-Philippe Suppini, PhD 04 94 14 53 00 ext +33 jean-philippe.suppini@ch-toulon.fr

Locations
Layout table for location information
France
AP-HM, Hôpital de la Conception
Marseille, Bouches-du-Rhône, France, 13005
Contact: Gilles KAPLANSKI, MD       gilles.kaplanski@ap-hm.fr   
Hôpital Sainte-Musse
Toulon, VAR, France, 83000
Contact: Gilles HITTINGER, MD    04 94145983 ext +33    Gilles.Hittinger@ch-toulon.fr   
Sainte Anne Teaching Military Hospital
Toulon, Var, France, 83000
Contact: David DELARBRE, MD    0483162891 ext 33    david.delarbre@intradef.gouv.fr   
Sponsors and Collaborators
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Hopital d'instruction des Armees Sainte-Anne
Assistance Publique Hopitaux De Marseille
Investigators
Layout table for investigator information
Principal Investigator: David DELARBRE, MD French Army Health Service
Publications of Results:
Layout table for additonal information
Responsible Party: Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
ClinicalTrials.gov Identifier: NCT04366232    
Other Study ID Numbers: 2020-CHITS-003
2020-001963-10 ( EudraCT Number )
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: May 22, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer:
COVID
SARS-CoV-2
Anakinra
Ruxolitinib
IL-1 inhibitors
JAK inhibitors
Additional relevant MeSH terms:
Layout table for MeSH terms
Inflammation
Pathologic Processes
Interleukin 1 Receptor Antagonist Protein
Antirheumatic Agents